Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec For Wet AMD

BenzingaMar 3 16:02 ET

Express News | Adverum Biotechnologies Initiates Artemis Phase 3 Study Evaluating Ixo-Vec for Wet AMD

ReutersMar 3 16:01 ET

Major Investment Alert: Adverum Biotechnologies Sees Significant Share Purchase!

TipRanksFeb 28 21:05 ET

Adverum Biotechnologies Insider Bought Shares Worth $1,439,087, According to a Recent SEC Filing

MT NewswiresFeb 28 16:08 ET

Analysts' Top Healthcare Picks: Adverum Biotechnologies (ADVM), Gilead Sciences (GILD)

TipRanksFeb 13 08:50 ET · Ratings

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

GlobeNewswireFeb 5 16:05 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

BenzingaDec 5, 2024 16:05 ET

Mizuho Securities Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Cuts Target Price to $16

Moomoo NewsNov 22, 2024 14:31 ET · Ratings

Adverum Biotechnologies Price Target Lowered to $16 From $20 at Mizuho

TipRanksNov 22, 2024 13:45 ET

Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained

MT NewswiresNov 22, 2024 13:28 ET · Ratings

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireNov 20, 2024 16:05 ET

Express News | Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 20, 2024 16:05 ET

Truist Financial Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating

Moomoo NewsNov 19, 2024 07:33 ET · Ratings

H.C. Wainwright Maintains Adverum Biotechnologies(ADVM.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsNov 19, 2024 03:36 ET · Ratings

Adverum Biotechnologies Advances Ixo-vec Gene Therapy Trials

TipRanksNov 18, 2024 16:36 ET

Buy Rating on Adverum Biotechnologies: Ixo-vec's Promising Potential in Transforming Wet AMD Treatment

TipRanksNov 18, 2024 12:35 ET · Ratings

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

MT NewswiresNov 18, 2024 08:16 ET

Express News | Adverum Biotechnologies Inc: 6E10 Dose in Luna Maintains Visual and Anatomic Endpoints

ReutersNov 18, 2024 07:03 ET

Express News | Adverum Biotechnologies Inc: Expects to Be Able to Fund Operations Into Second Half of 2025

ReutersNov 18, 2024 07:03 ET

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

GlobeNewswireNov 18, 2024 07:00 ET